{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:08:53Z","timestamp":1792174133546,"version":"4.4.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T00:00:00Z","timestamp":1726617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T00:00:00Z","timestamp":1726617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003009","name":"Science and Technology Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024743","name":"Suez Canal University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100024743","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A green and simple UPLC method was developed and optimized, adopting a factorial design for simultaneous determination of oseltamivir phosphate and remdesivir with dexamethasone as a co-administered drug in human plasma and using daclatasvir dihydrochloride as an internal standard within 5\u00a0min. The separation was established on UPLC column BEH C<jats:sub>18<\/jats:sub> 1.7\u00a0\u03bcm (2.1 <jats:inline-formula><jats:alternatives><jats:tex-math>$$\\times $$<\/jats:tex-math><mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\">\n                  <mml:mo>\u00d7<\/mml:mo>\n                <\/mml:math><\/jats:alternatives><\/jats:inline-formula> 100.0\u00a0mm) connected to UPLC pre-column BEH 1.7\u00a0\u03bcm (2.1 <jats:inline-formula><jats:alternatives><jats:tex-math>$$\\times $$<\/jats:tex-math><mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\">\n                  <mml:mo>\u00d7<\/mml:mo>\n                <\/mml:math><\/jats:alternatives><\/jats:inline-formula> 5.0\u00a0mm) at 50\u00a0\u00b0C with an injection volume of 10 \u03bcL. The photodiode array detector (PDA) was set at three wavelengths of 220, 315, and 245\u00a0nm for oseltamivir phosphate, the internal standard, and both dexamethasone and remdesivir, respectively. The mobile phase consisted of methanol and ammonium acetate solution (40\u00a0mM) adjusted to pH 4 in a ratio of 61.5:38.5 (v\/v) with a flow rate of 0.25\u00a0mL\u00a0min<jats:sup>\u22121<\/jats:sup>. The calibration curves were linear over 500.0\u20135000.0\u00a0ng\u00a0mL<jats:sup>\u22121<\/jats:sup> for oseltamivir phosphate, over 10.0\u2013500.0\u00a0ng\u00a0mL<jats:sup>\u22121<\/jats:sup> and 500.0\u20135000.0\u00a0ng\u00a0mL<jats:sup>\u22121<\/jats:sup> for dexamethasone, and over 20.0\u2013500\u00a0ng\u00a0mL<jats:sup>\u22121<\/jats:sup> and 500.0\u20135000.0\u00a0ng\u00a0mL<jats:sup>\u22121<\/jats:sup> for remdesivir. The Gibbs free energy and Van't Hoff plots were used to investigate the effect of column oven temperatures on retention times. Fluoride-EDTA anticoagulant showed inhibition activity on the esterase enzyme in plasma. The proposed method was validated according to the M10 ICH, FDA, and EMA\u2019s bioanalytical guidelines. According to Eco-score, GAPI, and AGREE criteria, the proposed method was considered acceptable green.<\/jats:p>","DOI":"10.1038\/s41598-024-71413-3","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T17:05:57Z","timestamp":1726765557000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["UPLC-PDA factorial design assisted method for simultaneous determination of oseltamivir, dexamethasone, and remdesivir in human plasma"],"prefix":"10.1038","volume":"14","author":[{"given":"Hanan I.","family":"EL-Shorbagy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona A.","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa","family":"El-Gindy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghada M.","family":"Hadad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fathalla","family":"Belal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,18]]},"reference":[{"key":"71413_CR1","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.bbrc.2020.11.015","volume":"538","author":"AA Gulyaeva","year":"2021","unstructured":"Gulyaeva, A. A. & Gorbalenya, A. E. A nidovirus perspective on SARS-CoV-2. Biochem. Biophys. Res. Commun. 538, 24\u201334 (2021).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"71413_CR2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41580-021-00432-z","volume":"23","author":"B Malone","year":"2022","unstructured":"Malone, B., Urakova, N., Snijder, E. J. & Campbell, E. A. Structures and functions of coronavirus replication\u2013transcription complexes and their relevance for SARS-CoV-2 drug design. Nat. Rev. Mol. Cell Biol. 23, 21\u201339. https:\/\/doi.org\/10.1038\/s41580-021-00432-z (2022).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"71413_CR3","doi-asserted-by":"publisher","first-page":"100895","DOI":"10.1016\/j.nmni.2021.100895","volume":"42","author":"M Shabani","year":"2021","unstructured":"Shabani, M., Sadegh Ehdaei, B., Fathi, F. & Dowran, R. A mini-review on sofosbuvir and daclatasvir treatment in coronavirus disease 2019. New Microbes New Infect. 42, 100895. https:\/\/doi.org\/10.1016\/j.nmni.2021.100895 (2021).","journal-title":"New Microbes New Infect."},{"key":"71413_CR4","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.3569866","author":"S Vafaei","year":"2020","unstructured":"Vafaei, S., Razmi, M., Mansoori, M., Asadi-Lari, M. & Madjd, Z. Spotlight of remdesivir in comparison with ribavirin, favipiravir, oseltamivir and umifenovir in coronavirus disease 2019 (COVID-19) pandemic. Lancet Infect. Dis. https:\/\/doi.org\/10.2139\/ssrn.3569866 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"71413_CR5","doi-asserted-by":"publisher","first-page":"104257","DOI":"10.1016\/j.bioorg.2020.104257","volume":"104","author":"Q Tan","year":"2020","unstructured":"Tan, Q. et al. Is oseltamivir suitable for fighting against COVID-19: In silico assessment, in vitro and retrospective study. Bioorg. Chem. 104, 104257. https:\/\/doi.org\/10.1016\/j.bioorg.2020.104257 (2020).","journal-title":"Bioorg. Chem."},{"key":"71413_CR6","doi-asserted-by":"publisher","first-page":"1818446","DOI":"10.1080\/20016689.2020.1818446","volume":"8","author":"T Qiu","year":"2020","unstructured":"Qiu, T. et al. Chinese guidelines related to novel coronavirus pneumonia. J. Mark. Access Health Policy 8, 1818446. https:\/\/doi.org\/10.1080\/20016689.2020.1818446 (2020).","journal-title":"J. Mark. Access Health Policy"},{"key":"71413_CR7","unstructured":"DrugBank. Remdesivir, https:\/\/go.drugbank.com\/drugs\/DB14761 (2019)."},{"key":"71413_CR8","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/psp4.12584","volume":"10","author":"PO Hanafin","year":"2021","unstructured":"Hanafin, P. O. et al. A mechanism-based pharmacokinetic model of remdesivir leveraging interspecies scaling to simulate COVID-19 treatment in humans. CPT Pharmacomet. Syst. Pharmacol. 10, 89\u201399. https:\/\/doi.org\/10.1002\/psp4.12584 (2021).","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"71413_CR9","unstructured":"EMA. Veklury, https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/veklury-epar-public-assessment-report_en.pdf (2020)."},{"key":"71413_CR10","unstructured":"Masoud, H. et al. Management protocol for COVID-19 patients MoHP protocol for COVID19 November 2020, https:\/\/www.researchgate.net\/publication\/345813633_Management_Protocol_for_COVID-19_Patients_MoHP_Protocol_for_COVID19_November_2020 (2020)."},{"key":"71413_CR11","unstructured":"FDA, U. S. The FDA approves first generic version of widely used influenza drug, Tamiflu, https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/fda-approves-first-generic-version-widely-used-influenza-drug-tamiflu#:~:text=On%20August%203%2C%202016%2C%20the,and%20prevention%20of%20the%20flu (2016)."},{"key":"71413_CR12","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1080\/10408347.2011.539416","volume":"41","author":"M Navas","year":"2011","unstructured":"Navas, M. & Jimenez, A. Analytical methods to determine anti-influenza drugs. Crit. Rev. Anal. Chem. 41, 81\u201397 (2011).","journal-title":"Crit. Rev. Anal. Chem."},{"key":"71413_CR13","first-page":"368","volume":"1","author":"ME Bosch","year":"2010","unstructured":"Bosch, M. E., Ojeda, C. B., S\u00e1nchez, A. J. R. & Rojas, F. S. Analytical methodologies for the determination of oseltamivir. Res. J. Pharm. Biol. Chem. Sci. 1, 368 (2010).","journal-title":"Res. J. Pharm. Biol. Chem. Sci."},{"key":"71413_CR14","first-page":"2786","volume":"2","author":"MQ Junaidy","year":"2014","unstructured":"Junaidy, M. Q., Haque, M. A. & Bakshi, V. RP-HPLC method development and validation for the estimation of oseltamivir phosphate in bulk form and pharmaceutical formulations. Int. J. Innov. Pharma. Sci. Res. 2, 2786\u20132791 (2014).","journal-title":"Int. J. Innov. Pharma. Sci. Res."},{"key":"71413_CR15","doi-asserted-by":"publisher","first-page":"5443","DOI":"10.13040\/IJPSR.0975-8232.10(12).5443-49","volume":"10","author":"VZ Ramya","year":"2019","unstructured":"Ramya, V. Z. & Gowda, Y. N. Simultaneous estimation of amantadine hydrochloride and oseltamivir phosphate using precolumn derivatization technique. Int. J. Pharm. Sci. Res. 10, 5443\u20135449. https:\/\/doi.org\/10.13040\/IJPSR.0975-8232.10(12).5443-49 (2019).","journal-title":"Int. J. Pharm. Sci. Res."},{"key":"71413_CR16","doi-asserted-by":"publisher","first-page":"41","DOI":"10.4137\/aci.S13878","volume":"9","author":"RI Al-Bagary","year":"2014","unstructured":"Al-Bagary, R. I., El-Zaher, A. A., Morsy, F. A. & Fouad, M. M. Kinetic study of the alkaline degradation of oseltamivir phosphate and valacyclovir hydrochloride using validated stability indicating HPLC. Anal. Chem. Insights 9, 41\u201348. https:\/\/doi.org\/10.4137\/aci.S13878 (2014).","journal-title":"Anal. Chem. Insights"},{"key":"71413_CR17","doi-asserted-by":"publisher","first-page":"161","DOI":"10.22159\/ajpcr.2021.v14i4.40595","volume":"14","author":"G Reddy","year":"2021","unstructured":"Reddy, G., Pulipaka, S., Krishna, R., Narayanarao, K. & Rapeti, D. Characterization of oseltamivir phosphate api and simultaneous quantification and validation of its impurities by UPLC. Asian J. Pharm. Clin. Res. 14, 161\u2013169. https:\/\/doi.org\/10.22159\/ajpcr.2021.v14i4.40595 (2021).","journal-title":"Asian J. Pharm. Clin. Res."},{"key":"71413_CR18","doi-asserted-by":"publisher","first-page":"91","DOI":"10.5958\/2231-5675.2016.00014.4","volume":"6","author":"S Reddy","year":"2016","unstructured":"Reddy, S. et al. Development and validation of two LCMS\/MS methods for simultaneous estimation of oseltamivir and its metabolite in human plasma and application in bioequivalence study. Asian J. Pharm. Anal. 6, 91\u2013101 (2016).","journal-title":"Asian J. Pharm. Anal."},{"key":"71413_CR19","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1007\/s00216-011-5581-3","volume":"402","author":"BJ Berendsen","year":"2012","unstructured":"Berendsen, B. J., Wegh, R. S., Essers, M. L., Stolker, A. A. & Weigel, S. Quantitative trace analysis of a broad range of antiviral drugs in poultry muscle using column-switch liquid chromatography coupled to tandem mass spectrometry. Anal. Bioanal. Chem. 402, 1611\u20131623 (2012).","journal-title":"Anal. Bioanal. Chem."},{"key":"71413_CR20","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s10895-017-2066-6","volume":"27","author":"MA Omar","year":"2017","unstructured":"Omar, M. A., Derayea, S. M. & Mostafa, I. M. Selectivity improvement for spectrofluorimetric determination of oseltamivir phosphate in human plasma and in the presence of its degradation product. Fluorescence 27, 1323\u20131330. https:\/\/doi.org\/10.1007\/s10895-017-2066-6 (2017).","journal-title":"Fluorescence"},{"key":"71413_CR21","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1021\/ac902277d","volume":"82","author":"TG Flick","year":"2010","unstructured":"Flick, T. G., Leib, R. D. & Williams, E. R. Direct standard-free quantitation of Tamiflu and other pharmaceutical tablets using clustering agents with electrospray ionization mass spectrometry. Anal. Chem. 82, 1179\u20131182. https:\/\/doi.org\/10.1021\/ac902277d (2010).","journal-title":"Anal. Chem."},{"key":"71413_CR22","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.msec.2013.12.040","volume":"37","author":"I Jebali","year":"2014","unstructured":"Jebali, I. & Belgaied, J.-E. A novel coated platinum electrode for oseltamivir determination in pharmaceuticals. Mater. Sci. Eng. C 37, 90\u201398. https:\/\/doi.org\/10.1016\/j.msec.2013.12.040 (2014).","journal-title":"Mater. Sci. Eng. C"},{"key":"71413_CR23","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1556\/1326.2021.00925","volume":"34","author":"S Gungor","year":"2022","unstructured":"Gungor, S., Bulduk, I., Sultan Ayd\u0131n, B. & Ilikci Sagkan, R. A comparative study of HPLC and UV spectrophotometric methods for oseltamivir quantification in pharmaceutical formulations. Acta Chromatogr. 34, 258\u2013266. https:\/\/doi.org\/10.1556\/1326.2021.00925 (2022).","journal-title":"Acta Chromatogr."},{"key":"71413_CR24","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1080\/10408347.2019.1581050","volume":"50","author":"MC Esposito","year":"2020","unstructured":"Esposito, M. C., Santos, A. L. A., Bonfilio, R. & de Ara\u00fajo, M. B. A critical review of analytical methods in pharmaceutical matrices for determination of corticosteroids. Crit. Rev. Anal. Chem. 50, 111\u2013124 (2020).","journal-title":"Crit. Rev. Anal. Chem."},{"key":"71413_CR25","doi-asserted-by":"publisher","first-page":"107580","DOI":"10.1016\/j.microc.2022.107580","volume":"179","author":"AA Emam","year":"2022","unstructured":"Emam, A. A., Abdelaleem, E. A., Abdelmomen, E. H., Abdelmoety, R. H. & Abdelfatah, R. M. Rapid and ecofriendly UPLC quantification of remdesivir, favipiravir and dexamethasone for accurate therapeutic drug monitoring in Covid-19 Patient\u2019s plasma. Microchem. J. 179, 107580. https:\/\/doi.org\/10.1016\/j.microc.2022.107580 (2022).","journal-title":"Microchem. J."},{"key":"71413_CR26","doi-asserted-by":"publisher","first-page":"122641","DOI":"10.1016\/j.jchromb.2021.122641","volume":"1171","author":"R Nguyen","year":"2021","unstructured":"Nguyen, R. et al. Development and validation of a simple, selective, and sensitive LC-MS\/MS assay for the quantification of remdesivir in human plasma. J. Chromatogr. B 1171, 122641. https:\/\/doi.org\/10.1016\/j.jchromb.2021.122641 (2021).","journal-title":"J. Chromatogr. B"},{"key":"71413_CR27","doi-asserted-by":"publisher","first-page":"e5212","DOI":"10.1002\/bmc.5212","volume":"35","author":"MM Hamdy","year":"2021","unstructured":"Hamdy, M. M., Abdel Moneim, M. M. & Kamal, M. F. Accelerated stability study of the ester prodrug remdesivir: Recently FDA-approved Covid-19 antiviral using reversed-phase-HPLC with fluorimetric and diode array detection. Biomed. Chromatogr. 35, e5212 (2021).","journal-title":"Biomed. Chromatogr."},{"key":"71413_CR28","first-page":"1","volume":"3","author":"E Deniz","year":"2021","unstructured":"Deniz, E., \u00d6zaltin, N. & Yilmaz, S. A review on recent electroanalytical methods for the analysis of antiviral COVID-19 drugs. Turk. J. Chem. 3, 1\u20138 (2021).","journal-title":"Turk. J. Chem."},{"key":"71413_CR29","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1039\/D1AY00469G","volume":"13","author":"H Elmansi","year":"2021","unstructured":"Elmansi, H., Ibrahim, A. E., Mikhail, I. E. & Belal, F. Green and sensitive spectrofluorimetric determination of remdesivir, an FDA approved SARS-CoV-2 candidate antiviral; application in pharmaceutical dosage forms and spiked human plasma. Anal. Methods 13, 2596\u20132602. https:\/\/doi.org\/10.1039\/D1AY00469G (2021).","journal-title":"Anal. Methods"},{"key":"71413_CR30","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1007\/s10337-013-2477-8","volume":"76","author":"M Gumustas","year":"2013","unstructured":"Gumustas, M., Kurbanoglu, S., Uslu, B. & Ozkan, S. A. UPLC versus HPLC on drug analysis: Advantageous, applications and their validation parameters. Chromatographia 76, 1365\u20131427 (2013).","journal-title":"Chromatographia"},{"key":"71413_CR31","unstructured":"Bioanalytical method validation and study sample analysis M10. ICH Harmonised Guideline: Geneva, Switzerland (2022)."},{"key":"71413_CR32","doi-asserted-by":"publisher","first-page":"67","DOI":"10.17145\/jab.18.010","volume":"4","author":"R Meesters","year":"2018","unstructured":"Meesters, R. & Voswinkel, S. Bioanalytical method development and validation: From the USFDA 2001 to the USFDA 2018 guidance for industry. J. Appl. Bioanal. 4, 67\u201373 (2018).","journal-title":"J. Appl. Bioanal."},{"key":"71413_CR33","doi-asserted-by":"publisher","first-page":"865","DOI":"10.4155\/bio.12.44","volume":"4","author":"G Smith","year":"2012","unstructured":"Smith, G. European medicines agency guideline on bioanalytical method validation: What more is there to say?. Bioanalysis 4, 865\u2013868 (2012).","journal-title":"Bioanalysis"},{"key":"71413_CR34","doi-asserted-by":"publisher","first-page":"10076","DOI":"10.1021\/acs.analchem.0c01887","volume":"92","author":"F Pena-Pereira","year":"2020","unstructured":"Pena-Pereira, F., Wojnowski, W. & Tobiszewski, M. AGREE\u2014Analytical greenness metric approach and software. Anal. Chem. 92, 10076\u201310082. https:\/\/doi.org\/10.1021\/acs.analchem.0c01887 (2020).","journal-title":"Anal. Chem."},{"key":"71413_CR35","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.trac.2012.03.013","volume":"37","author":"A Ga\u0142uszka","year":"2012","unstructured":"Ga\u0142uszka, A., Migaszewski, Z. M., Konieczka, P. & Namie\u015bnik, J. Analytical Eco-Scale for assessing the greenness of analytical procedures. Trends Anal. Chem. 37, 61\u201372 (2012).","journal-title":"Trends Anal. Chem."},{"key":"71413_CR36","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.talanta.2018.01.013","volume":"181","author":"J P\u0142otka-Wasylka","year":"2018","unstructured":"P\u0142otka-Wasylka, J. A new tool for the evaluation of the analytical procedure: Green Analytical Procedure Index. Talanta 181, 204\u2013209. https:\/\/doi.org\/10.1016\/j.talanta.2018.01.013 (2018).","journal-title":"Talanta"},{"key":"71413_CR37","unstructured":"Yi, X., Shi, W., Yu, S. & Li, X. MINITAB\u00ae release 16 statistical software for windows. https:\/\/www.minitab.com\/en-us\/products\/minitab\/ (2011)."},{"key":"71413_CR38","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jpba.2011.04.023","volume":"56","author":"B Dejaegher","year":"2011","unstructured":"Dejaegher, B. & Heyden, Y. V. Experimental designs and their recent advances in set-up, data interpretation, and analytical applications. J. Pharm. Biomed. Anal. 56, 141\u2013158. https:\/\/doi.org\/10.1016\/j.jpba.2011.04.023 (2011).","journal-title":"J. Pharm. Biomed. Anal."},{"key":"71413_CR39","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.microc.2019.03.039","volume":"147","author":"HI El-Shorbagy","year":"2019","unstructured":"El-Shorbagy, H. I., Elsebaei, F., Hammad, S. F. & El-Brashy, A. M. Optimization and modeling of a green dual detected RP-HPLC method by UV and fluorescence detectors using two level full factorial design for simultaneous determination of sofosbuvir and ledipasvir: Application to average content and uniformity of dosage unit testing. Microchem. J. 147, 374\u2013392. https:\/\/doi.org\/10.1016\/j.microc.2019.03.039 (2019).","journal-title":"Microchem. J."},{"key":"71413_CR40","doi-asserted-by":"publisher","first-page":"5466","DOI":"10.1038\/s41598-023-32405-x","volume":"13","author":"HI El-Shorbagy","year":"2023","unstructured":"El-Shorbagy, H. I., Mohamed, M. A., El-Gindy, A., Hadad, G. M. & Belal, F. Development of UPLC method for simultaneous assay of some COVID-19 drugs utilizing novel instrumental standard addition and factorial design. Sci. Rep. 13, 5466. https:\/\/doi.org\/10.1038\/s41598-023-32405-x (2023).","journal-title":"Sci. Rep."},{"key":"71413_CR41","unstructured":"Waters. ACQUITY UPLC\u00ae BEH C18 and C8 columns by Waters, https:\/\/www.selectscience.net\/products\/acquity-uplc-beh-c18-and-c8-columns\/?prodID=79501#tab-2 (2020)."},{"key":"71413_CR42","unstructured":"Waters. Column particle technologies, https:\/\/www.waters.com\/waters\/en_US\/BEH-(Ethylene-Bridged-Hybrid)-Technology\/nav.htm?cid=134618172&locale=en_US (2022)."},{"key":"71413_CR43","first-page":"776","volume":"15","author":"GW Tindall","year":"2002","unstructured":"Tindall, G. W. & Dolan, J. W. The interpretation of pH in partially aqueous mobile phases. LC GC Europe 15, 776\u2013779 (2002).","journal-title":"LC GC Europe"},{"key":"71413_CR44","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0021-9673(00)96168-5","volume":"316","author":"CK Lim","year":"1984","unstructured":"Lim, C. K. & Peters, T. J. Ammonium acetate: A general purpose buffer for clinical applications of high-performance liquid chromatography. J. Chromatogr. A 316, 397\u2013406. https:\/\/doi.org\/10.1016\/S0021-9673(00)96168-5 (1984).","journal-title":"J. Chromatogr. A"},{"key":"71413_CR45","first-page":"572","volume":"31","author":"B Boyes","year":"2018","unstructured":"Boyes, B. & Dong, M. Modern trends and best practices in mobile-phase selection in reversed-phase chromatography. LC GC Europe 31, 572\u2013583 (2018).","journal-title":"LC GC Europe"},{"key":"71413_CR46","first-page":"590","volume":"19","author":"NS Wilson","year":"2001","unstructured":"Wilson, N. S., Morrison, R. & Dolan, J. W. Buffers and baselines. LC GC Europe 19, 590\u2013595 (2001).","journal-title":"LC GC Europe"},{"key":"71413_CR47","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1691\/ph.2014.3223","volume":"69","author":"E Pi\u00f3rkowska","year":"2014","unstructured":"Pi\u00f3rkowska, E., Kaza, M., Fitatiuk, J., Szlaska, I. & Rudzki, P. Rapid and simplified HPLC-UV method with on-line wavelengths switching for determination of capecitabine in human plasma. Die Pharmazie 69, 500\u2013505. https:\/\/doi.org\/10.1691\/ph.2014.3223 (2014).","journal-title":"Die Pharmazie"},{"key":"71413_CR48","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.aca.2019.05.063","volume":"1078","author":"S Soriano-Meseguer","year":"2019","unstructured":"Soriano-Meseguer, S., Fuguet, E., Port, A. & Ros\u00e9s, M. Influence of the acid-base ionization of drugs in their retention in reversed-phase liquid chromatography. Anal. Chim. Acta 1078, 200\u2013211. https:\/\/doi.org\/10.1016\/j.aca.2019.05.063 (2019).","journal-title":"Anal. Chim. Acta"},{"key":"71413_CR49","unstructured":"DrugBank. Favipiravir, https:\/\/go.drugbank.com\/drugs\/DB12466 (2021)."},{"key":"71413_CR50","unstructured":"DrugBank. Daclatasvir dihydrochloride, https:\/\/go.drugbank.com\/salts\/DBSALT001166 (2015)."},{"key":"71413_CR51","unstructured":"DrugBank. Ledipasvir, https:\/\/www.drugbank.ca\/drugs\/DB09027 (2022)."},{"key":"71413_CR52","first-page":"60","volume":"12","author":"MA Wadie","year":"2017","unstructured":"Wadie, M. A., Mostafa, S. M., El Adl, S. M. & Elgawish, M. S. Development and validation of a new, simple-hplc method for simultaneous determination of sofosbuvir, daclatasvir and ribavirin in tablet dosage form. J. Pharm. Biol. Sci. 12, 60\u201368 (2017).","journal-title":"J. Pharm. Biol. Sci."},{"key":"71413_CR53","unstructured":"Ng, L. L. Reviewer guidance: Validation of chromatographic methods, https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/reviewer-guidance-validation-chromatographic-methods (1994)."},{"key":"71413_CR54","unstructured":"Li, J. B. Effect of temperature on column pressure, peak retention time and peak shape, https:\/\/www.waters.com\/webassets\/cms\/library\/docs\/watersamd30.pdf (2023)."},{"key":"71413_CR55","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S0021-9673(00)80355-6","volume":"196","author":"JS Kowalczyk","year":"1980","unstructured":"Kowalczyk, J. S. & Herbut, G. Influence of temperature on separation processes in adsorption liquid chromatographic systems. J. Chromatogr. A 196, 11\u201320. https:\/\/doi.org\/10.1016\/S0021-9673(00)80355-6 (1980).","journal-title":"J. Chromatogr. A"},{"key":"71413_CR56","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0021-9673(00)01226-7","volume":"920","author":"P Hatsis","year":"2001","unstructured":"Hatsis, P. & Lucy, C. Effect of temperature on retention and selectivity in ion chromatography of anions. J. Chromatogr. A 920, 3\u201311. https:\/\/doi.org\/10.1016\/S0021-9673(00)01226-7 (2001).","journal-title":"J. Chromatogr. A"},{"key":"71413_CR57","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/0731-7085(96)01838-9","volume":"15","author":"H Rosing","year":"1996","unstructured":"Rosing, H., Doyle, E. & Beijnen, J. H. The impact of column temperature in the high performance liquid chromatographic analysis of topotecan in rat and dog plasma. J. Pharm. Biomed. Anal. 15, 279\u2013286. https:\/\/doi.org\/10.1016\/0731-7085(96)01838-9 (1996).","journal-title":"J. Pharm. Biomed. Anal."},{"key":"71413_CR58","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.chroma.2016.01.043","volume":"1435","author":"E Caiali","year":"2016","unstructured":"Caiali, E., David, V., Aboul-Enein, H. Y. & Moldoveanu, S. C. Evaluation of the phase ratio for three C18 high performance liquid chromatographic columns. J. Chromatogr. A 1435, 85\u201391. https:\/\/doi.org\/10.1016\/j.chroma.2016.01.043 (2016).","journal-title":"J. Chromatogr. A"},{"key":"71413_CR59","unstructured":"DrugBank. Oseltamivir, https:\/\/go.drugbank.com\/drugs\/DB00198 (2024)."},{"key":"71413_CR60","unstructured":"DrugBank. Dexamethasone, https:\/\/go.drugbank.com\/drugs\/DB01234 (2005)."},{"key":"71413_CR61","doi-asserted-by":"publisher","first-page":"7772","DOI":"10.1021\/acsomega.7b01445","volume":"2","author":"S Tshepelevitsh","year":"2017","unstructured":"Tshepelevitsh, S. et al. Systematic optimization of liquid\u2013liquid extraction for isolation of unidentified components. ACS Omega 2, 7772\u20137776. https:\/\/doi.org\/10.1021\/acsomega.7b01445 (2017).","journal-title":"ACS Omega"},{"key":"71413_CR62","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/B978-0-12-802444-7.00009-4","volume-title":"Principles of Organic Chemistry","author":"RJ Ouellette","year":"2015","unstructured":"Ouellette, R. J. & Rawn, J. D. In Principles of Organic Chemistry (eds Ouellette, R. J. & David Rawn, J.) 239\u2013258 (Elsevier, 2015)."},{"key":"71413_CR63","doi-asserted-by":"publisher","first-page":"ii5","DOI":"10.1093\/jac\/dkq015","volume":"65","author":"BE Davies","year":"2010","unstructured":"Davies, B. E. Pharmacokinetics of oseltamivir: An oral antiviral for the treatment and prophylaxis of influenza in diverse populations. J. Antimicrob. Chemother. 65, ii5\u2013ii10. https:\/\/doi.org\/10.1093\/jac\/dkq015 (2010).","journal-title":"J. Antimicrob. Chemother."},{"key":"71413_CR64","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jpba.2019.02.004","volume":"168","author":"Z Li","year":"2019","unstructured":"Li, Z., Zhang, J., Zhang, Y. & Zuo, Z. Role of esterase mediated hydrolysis of simvastatin in human and rat blood and its impact on pharmacokinetic profiles of simvastatin and its active metabolite in rat. J. Pharm. Biomed. Anal. 168, 13\u201322. https:\/\/doi.org\/10.1016\/j.jpba.2019.02.004 (2019).","journal-title":"J. Pharm. Biomed. Anal."},{"key":"71413_CR65","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jchromb.2012.02.026","volume":"891\u2013892","author":"W Kromdijk","year":"2012","unstructured":"Kromdijk, W., Rosing, H., van den Broek, M. P., Beijnen, J. H. & Huitema, A. D. Quantitative determination of oseltamivir and oseltamivir carboxylate in human fluoride EDTA plasma including the ex vivo stability using high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 891\u2013892, 57\u201363. https:\/\/doi.org\/10.1016\/j.jchromb.2012.02.026 (2012).","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"71413_CR66","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1177\/00912700022009567","volume":"40","author":"JW Massarella","year":"2000","unstructured":"Massarella, J. W. et al. The pharmacokinetics and tolerability of the oral neuraminidase inhibitor oseltamivir (Ro 64\u20130796\/GS4104) in healthy adult and elderly volunteers. J. Clin. Pharmacol. 40, 836\u2013843. https:\/\/doi.org\/10.1177\/00912700022009567 (2000).","journal-title":"J. Clin. Pharmacol."},{"key":"71413_CR67","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/bf00614309","volume":"30","author":"D Loew","year":"1986","unstructured":"Loew, D., Schuster, O. & Graul, E. H. Dose-dependent pharmacokinetics of dexamethasone. Eur. J. Clin. Pharmacol. 30, 225\u2013230. https:\/\/doi.org\/10.1007\/bf00614309 (1986).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"71413_CR68","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/bcp.12295","volume":"78","author":"SMC Spoorenberg","year":"2014","unstructured":"Spoorenberg, S. M. C. et al. Pharmacokinetics of oral vs. intravenous dexamethasone in patients hospitalized with community-acquired pneumonia. Br. J. Clin. Pharmacol. 78, 78\u201383. https:\/\/doi.org\/10.1111\/bcp.12295 (2014).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"71413_CR69","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/bf02455994","volume":"32","author":"ME Brady","year":"1987","unstructured":"Brady, M. E., Sartiano, G. P., Rosenblum, S. L., Zaglama, N. E. & Bauguess, C. T. The pharmacokinetics of single high doses of dexamethasone in cancer patients. Eur. J. Clin. Pharmacol. 32, 593\u2013596. https:\/\/doi.org\/10.1007\/bf02455994 (1987).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"71413_CR70","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00280-008-0713-y","volume":"63","author":"S Nakade","year":"2008","unstructured":"Nakade, S. et al. Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting. Cancer Chemother. Pharmacol. 63, 75\u201383. https:\/\/doi.org\/10.1007\/s00280-008-0713-y (2008).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"71413_CR71","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1111\/cts.12840","volume":"13","author":"R Humeniuk","year":"2020","unstructured":"Humeniuk, R. et al. Safety, tolerability, and pharmacokinetics of remdesivir, an antiviral for treatment of COVID-19, in healthy subjects. Clin. Transl. Sci. 13, 896\u2013906 (2020).","journal-title":"Clin. Transl. Sci."},{"key":"71413_CR72","doi-asserted-by":"publisher","first-page":"104555","DOI":"10.1016\/j.microc.2019.104555","volume":"154","author":"T Elawady","year":"2020","unstructured":"Elawady, T., Khedr, A., El-Enany, N. & Belal, F. LC-MS\/MS determination of erdafitinib in human plasma after SPE: Investigation of the method greenness. Microchem. J. 154, 104555. https:\/\/doi.org\/10.1016\/j.microc.2019.104555 (2020).","journal-title":"Microchem. J."},{"key":"71413_CR73","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.bfopcu.2017.04.003","volume":"55","author":"EG Nouman","year":"2017","unstructured":"Nouman, E. G., Al-Ghobashy, M. A. & Lotfy, H. M. Development and validation of LC-MS\/MS assay for the determination of Butoconazole in human plasma: Evaluation of systemic absorption following topical application in healthy volunteers. Bull. Fac. Pharm. Cairo Univ. 55, 303\u2013310. https:\/\/doi.org\/10.1016\/j.bfopcu.2017.04.003 (2017).","journal-title":"Bull. Fac. Pharm. Cairo Univ."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-71413-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-71413-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-71413-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T10:01:47Z","timestamp":1726912907000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-71413-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,18]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["71413"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-71413-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,18]]},"assertion":[{"value":"22 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"We confirm that all experiments were performed in accordance with relevant guidelines and regulations. The study was conducted according to the rules of the Ethics Committee at the Faculty of Pharmacy, Suez Canal University (number: 202009PHDH1). Informed consent was obtained from all subjects and\/or their legal guardian(s). The duration of the study was within 1\u00a0month and parallel. The retention of the sample in the ultra-low deep freezer was for 7\u00a0days. The preparation of spiked solutions for validation was concurrent with the study. The preparation of spiked samples for analysis of the study sample was done after validation and preserved for 1\u00a0week.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"21758"}}